Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0000875320-24-000051 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-13 | 2024-02-09 | VRTX | Kewalramani Reshma | CEO, Pres, Dir | F - Tax | $422.74 | -8,255 | 162.3K | -5% | -$3.49M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-09 | F | D | 8,255 | $422.74 | 162,271 | D | — | — |